DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for dengue disease — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDengue disease maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dengue disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
furin, paired basic amino acid cleaving enzyme (FURIN) — FURIN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-{[2-(3,5-dichlorophenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7LCU · 1.24 Å · ligand (1-{[2-(3,5-dichlorophenyl)-6-{[2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]oxy}pyridin-4-yl]methyl}piperidin-4-yl)acetic acid (XTA). Experimental structure, not a prediction.
What the evidence adds up to
Dengue viral infections are caused by one of four single-stranded RNA viruses of the family Flaviviridae and transmitted by the mosquito vector Aedes aegypti. The clinical syndromes exist along a continuum; most cases are asymptomatic and few present with severe forms characterised by shock. Management is predominantly supportive and includes methods to judiciously resolve shock and control bleeding while preventing fluid overload. Treatment is supportive, and outcomes can be optimised by early recognition and cautious titrated fluid replacement, especially in resource-limited environments. There is no specific therapy for dengue infections.
A 2018 series of 10 dengue cases from Sri Lanka (mean age 27 years, range 12–51, 6 females, 4 males) included 7 with dengue haemorrhagic fever and 3 with dengue fever. Two primary infections had severe bleeding into the gut. Other life-threatening problems were acute severe hepatitis, severe septic shock, myocarditis, erratic rapid plasma leak, intracranial bleeding, diarrhoea, and decompensated dengue shock due to third-space fluid leak. Blood transfusions and other empirical therapeutic methods were used alongside meticulous fluid management. Bedside ultrasound scanning helped early detection of the critical phase. All 10 patients recovered fully.
Dengue is endemic in more than 128 countries, and nearly forty percent of the world population is at risk of contracting the infection. There are no available antiviral treatments; only supportive care exists as the sole form of treatment. Some vaccines and antiviral agents are under clinical trials but their results have not been reported or approved yet. Preventive measures using plant extracts have shown some promising ovicidal activity against Aedes aegypti, but no successful permanent cure has been invented.
What is still missing is any specific antiviral therapy or vaccine that has completed clinical trials and been approved for dengue. Research addressing pathophysiological differences between dengue shock and septic shock, choice of fluids, inotropes, and techniques of organ support is needed. The therapeutic window for unusual presentations is very short, and these complications are underreported and often overlooked. No drug repurposing data are presented in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Critical Care Medicine · 2010 · 234 citations
Dengue hemorrhagic fever and shock syndromes*
AbstractOBJECTIVES: To provide a comprehensive review of dengue, with an emphasis on clinical syndromes, classification, diagnosis, and management, and to outline relevant aspects of epidemiology, immunopathogenesis, and prevention strategies. Dengue, a leading cause of childhood mortality in Asia and South America, is the most rapidly spreading and important arboviral disease in the world and has a geographic distribution of > 100 countries. DATA SOURCE: Boolean searches were carried out by using PubMed from 1975 to March 2009 and the Cochrane Database of Systematic Reviews from 1993 to March 2009 to identify potentially relevant articles by key search terms such as: "dengue"; "dengue fever"; "dengue hemorrhagic fever"; "dengue shock syndrome"; "severe dengue" and "immunopathogenesis," pathogenesis," "classification," "complications," and "management." In addition, authoritative seminal and up-to-date reviews by experts were used. STUDY SELECTION: Original research and up-to-date reviews and authoritative reviews consensus statements relevant to diagnosis and therapy were selected. DATA EXTRACTION AND SYNTHESIS: We considered the most relevant articles that would be important and of interest to the critical care practitioner as well as authoritative consensus statements from the World Health Organization and the Centers for Disease Control and Prevention. Dengue viral infections are caused by one of four single-stranded ribonucleic acid viruses of the family Flaviviridae and are transmitted by their mosquito vector, Aedes aegypti. The clinical syndromes caused by dengue viral infections occur along a continuum; most cases are asymptomatic and few present with severe forms characterized by shock. Management is predominantly supportive and includes methods to judiciously resolve shock and control bleeding while at the same time preventing fluid overload. CONCLUSIONS: Dengue is no longer confined to the tropics and is a global disease. Treatment is supportive. Outcomes can be optimized by early recognition and cautious titrated fluid replacement, especially in resource-limited environments.
Dengue and dengue hemorrhagic fever: management issues in an intensive care unit
AbstractOBJECTIVES: To describe the epidemiology, clinical features and treatment of dengue fever and dengue shock syndrome. SOURCES: To prepare this review, a literature search was made on PubMed and on the World Health Organization (WHO) and PAHO websites using the terms dengue and dengue shock syndrome. This information was complemented with personal practice. SUMMARY OF THE FINDINGS: Dengue is the most important arthropod-borne viral disease of humans. Its presentation is protean and varies from an undifferentiated viral syndrome to hemorrhagic fever and severe shock. Dengue fever is a self-limiting, nonspecific illness characterized by fever, headache, myalgia, and constitutional symptoms. Its severe forms (hemorrhagic fever and shock syndrome) may lead to multisystem involvement and death. Early diagnosis, close monitoring for deterioration and response to treatment are necessary in all cases. WHO has provided a stepwise approach to management that is useful for milder forms and early shock. In the more severe forms aggressive fluid resuscitation and support for failing organs is necessary for the critically ill patient. Research addressing pathophysiological differences between dengue shock and septic shock, choice of fluids, inotropes and techniques of organ support are likely to yield benefits for the critically ill. CONCLUSIONS: There is no specific therapy for dengue infections. Good supportive care may be lifesaving, but ultimately initiatives aimed at vector control and prevention of mosquito bites may provide the greatest benefits.
Series of 10 dengue fever cases with unusual presentations and complications in Sri Lanka: a single centre experience in 2016
AbstractBACKGROUND: Dengue has global importance as a dreaded arboviral infection. It has 4 serotypes of epidemiological imporatnce. The classification denotes two clinical spectrums- dengue fever (DF) and dengue haemorragic fever (DHF). Most cases are stereotype and amenable to fluid resuscitation. However, unusual manifestations cause fatalities and often overlooked. This study describes 10 such dengue cases to fill the knowledge gaps. CASE PRESENTATION: All 10 patients presented to the Teaching Hospital, Peradeniya, Sri Lanka during mid-year epidemic of dengue in 2016. The mean age is 27 years (range 12-51 years) comprising 6 females and 4 males. The group had 7 DHF, 3 DF and 2 primary dengue infections who predominantly had severe bleeding into gut. Other potentially life threatening problems were acute severe hepatitis, severe septic shock, myocarditis, erratic rapid plasma leak, intracranial bleeding, diarrhoea and decompenstaed dengue shock due to 3rd space fluid leak. Blood transfusions and other empirical therapeutic methods were used apart from meticulous fluid management to suit issues of each patient. Bedside ultrasound scanning helped early detection of critical phase. All recovered fully. CONCLUSIONS: Dengue is an extremely challenging infection to treat in the globe today. Above unusual presentation and complications could be fatal, if not detected early where therapeutic window period is very short. Clinicians need awareness of these problems which are not uncommon, but underreported and often overlooked. The clinical management of each patient was described for the purpose sharing the experiences.
Book Publisher International (a part of SCIENCEDOMAIN International) · 2022 · 1 citations
Dengue Virus Infection: Current Perspectives
AbstractDengue fever is a disease that is caused by five dengue virus (DENV) serotypes. It is endemic in more than 128 countries. Millions of people are affected by this disease. But still, there is no specific treatment available till now to combat it. Some of the preventive measures using plant extracts showed certain promising ovicidal activity against Aedes aegypti. There are some vaccines as preventive measures and antiviral agents to cure the dengue fever, which are under clinical trials but their results have not been reported or approved yet. Scientific research has been going on to find a permanent cure for dengue fever, but till now, no successful invention has been done. There are some general treatments for dengue patients by employing analgesics and fluid replacement; however, specific treatment is needed to overcome the lethal effect of dengue fever.
Journal of Transmitted Diseases and Immunity · 2021 · 0 citations
Why there are No Vaccines for Dengue Hemorrhagic Fever so Far
AbstractDengue is life threatening and rapidly emerging falviviral infection transmitted by mosquito vector and having significant socio economic impact. This disease is widely prevalent in the tropical and subtropical climates. Currently nearly forty percent of the world population is at the risk of contracting the dengue infection. Presently, only supportive care only exists as the sole form of treatment as there are no available antiviral treatments. There have been several studies on the epidemiology, transmission, screening, diagnosis, pathogenesis, prevention, control and treatment of dengue.
Disease module: DeepOracle (Open Targets). Approved indication: ChEMBL drug_indication (max_phase=4). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
